OxyContin maker Purdue Pharma to stop marketing opioids to doctors
Purdue Pharma, the company behind prescription painkiller OxyContin said it will stop marketing opioid drugs to doctors, bowing to a key demand of lawsuits that blame the company for helping trigger the current drug abuse epidemic.
The company announced its surprise reversal on Saturday. Purdue’s statement said it eliminated more than half its sales staff this week and will no longer send sales representatives to doctors’ offices to discuss opioid drugs, starting Monday. Its remaining sales staff of about 200 will focus on other medications.
“We have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers,” the company said in a written statement.
OxyContin has long been the world’s top-selling opioid painkiller. It generated billions in sales for privately-held Purdue. The pill, a time-release version of oxycodone, was hailed as a breakthrough treatment for chronic pain when it was approved in late 1995. But some users quickly discovered they could get a heroin-like high by crushing the pills and snorting or injecting the entire dose at once.
Purdue’s promotions exaggerated the drug’s safety and risks of addiction, leaning heavily on one sentence: “Delayed absorption as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug.” Sales rep used the sentence to market the drug to doctors. The company’s approach lead to lawsuits and federal investigations. But the painkiller continued to rack up blockbuster sales.
After launching, Purdue marketed OxyContin aggressively, according to documents obtained by Marketplace. “Dedicate 70% of your time selling Oxycontin!!!!!!!!!!!” reads a sales strategy memo dated Feb. 27, 2000. “We are selling Oxycontin 70% of the time!!!!!” reads another. “Remember to sell Oxycontin 70% of the time,” reads a less enthusiastic email dated March 1, 2000.
At the heart of Purdue’s sales tactics was an unusual marketing guide, based on the children’s classic “The Wizard of Oz.” Marketplace obtained a copy of a Purdue Pharma sales document, called “IF I ONLY HAD A BRAIN…” It was stamped “Training & Development,” and sent out to the “Entire Field Force” from the sales department on Nov. 4, 1996. In the document, Purdue offers its sales reps a guide to convincing doctors to prescribe OxyContin.
That step-by-step guide was built on “The Wizard of Oz,” complete with munchkins, Auntie Em, Dorothy, and the Yellow Brick Road.
According to a GAO report, Purdue spent approximately six to 12 times more on promotional efforts during OxyContin’s first six years on the market than it had spent on its older product, MS Contin, during its first six years, or than had been spent by Janssen Pharmaceutical Products L.P., for one of OxyContin’s drug competitors, Duragesic.
And its efforts worked: OxyContin became one of the most prescribed narcotics in the country. Purdue has made over $35 billion in sales from OxyContin since it began marketing the drug in 1996, according to data from IQVIA. And OxyContin also became one of the most abused pharmaceutical drugs in U.S. history.
The sentence would remain on OxyContin’s label for more than five years before the FDA removed it and put a “black box warning” on the drug, signifying the drug’s serious or life-threatening risks.
Listen to The Uncertain Hour to hear how that highly-marketed sentence helped set off the opioid crisis.
Updated: This story was updated to include Purdue’s statement.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.